Robert J Levy

Address:

3062 NE 49 St, Ft Lauderdale, FL 33308

VIN:

WBAWB33537PV72398

Make:

BMW

Model:

3 SERIES

Year:

2007

US Patent:

20070128184, Jun 7, 2007

Filed:

Aug 30, 2006

Appl. No.:

11/512412

Inventors:

Eckhard Podack - Miami FL, US
Vadim Deyev - Miami FL, US
Robert Levy - Cooper City FL, US

International Classification:

A61K 39/395
C07K 16/46
C07K 16/28

US Classification:

424143100, 530388220, 424178100, 530391100

Abstract:

It is an object of the invention to provide novel compositions and methods utilizing immunomodulating agents that can either stimulate or indirectly augment the immune system or in other cases have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, among other things, to treat disease caused by asthma and chronic inflammation such as for example inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein are capable of inhibiting CD8 T cell-mediated cellular immune responses and can for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines. TNFR25 specific immunotoxins disclosed herein are also capable of increasing the effectiveness of a chemotherapeutic regimen by depleting a cancer patient of naturally occurring immunosuppressive cells.

US Patent:

20110243951, Oct 6, 2011

Filed:

Aug 3, 2009

Appl. No.:

12/534228

Inventors:

Eckhard R. Podack - Coconut Grove FL, US
Vadim Deyev - Miami FL, US
Robert Levy - Cooper City FL, US

Assignee:

University of Miami - Miami FL

International Classification:

A61K 39/395
A61P 29/00
A61P 11/00

US Classification:

4241451, 4241581

Abstract:

It is an object of the invention to provide novel compositions and methods utilizing immunomodulating agents that can either stimulate or indirectly augment the immune system or in other cases have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, among other things, to treat disease caused by asthma and chronic inflammation such as for example inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein are capable of inhibiting CD8 T cell-mediated cellular immune responses and can for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines. TNFR25 specific immunotoxins disclosed herein are also capable of increasing the effectiveness of a chemotherapeutic regimen by depleting a cancer patient of naturally occurring immunosuppressive cells.

US Patent:

20120321645, Dec 20, 2012

Filed:

Apr 27, 2012

Appl. No.:

13/457583

Inventors:

Eckhard R. Podack - Coconut Grove FL, US
Vadim Deyev - Miami FL, US
Robert Levy - Cooper City FL, US

Assignee:

UNIVERSITY OF MIAMI - Coral Gables FL

International Classification:

A61K 39/00
A61P 37/04
A61P 35/00
A61K 39/395

US Classification:

4241731, 4241841, 4242771

Abstract:

Compositions and methods utilizing immunomodulating agents can either stimulate or indirectly augment the immune system or have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used to treat disease caused by asthma and chronic inflammation such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein are capable of inhibiting CD8 T cell-mediated cellular immune responses and can for example, mitigate organ or tissue rejection following a tissue transplantation.

US Patent:

D4372107, Feb 6, 2001

Filed:

May 7, 1999

Appl. No.:

D/104593

Inventors:

Dominic A. Borotto - Hollywood FL
Robert L. Levy - North Miami Beach FL
Bill E. Kushner - Aventura FL

Assignee:

Taco Metals, Inc. - Miami FL

International Classification:

0808

US Classification:

D 8396

US Patent:

D4513649, Dec 4, 2001

Filed:

Jun 12, 2000

Appl. No.:

D/124778

Inventors:

Dominic A. Borotto - Hollywood FL
Robert L. Levy - North Miami Beach FL
Bill E. Kushner - Aventura FL

Assignee:

Taco Metals, Inc. - Miami FL

International Classification:

0806

US Classification:

D 8323

US Patent:

D4513711, Dec 4, 2001

Filed:

Jun 12, 2000

Appl. No.:

D/124777

Inventors:

Dominic A. Borotto - Hollywood FL
Robert L. Levy - North Miami Beach FL
Bill E. Kushner - Aventura FL

Assignee:

Taco Metals, Inc. - Miami FL

International Classification:

0808

US Classification:

D 8396

US Patent:

20230034174, Feb 2, 2023

Filed:

Jun 14, 2022

Appl. No.:

17/839963

Inventors:

- Miami FL, US
Vadim DEYEV - Miami FL, US
Robert LEVY - Cooper City FL, US

International Classification:

A61K 38/17
C07K 16/28
C07K 16/24
A61K 35/13
A61K 39/00
A61K 39/395
A61K 45/06

Abstract:

This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, e.g., to treat disease caused by asthma and chronic inflammation, such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein can inhibit CD8 T cell-mediated cellular immune responses and can, for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines. TNFR25 specific immunotoxins disclosed herein are also capable of increasing the effectiveness of a chemotherapeutic regimen by depleting a cancer patient of naturally occurring immunosuppressive cells.

US Patent:

20200345809, Nov 5, 2020

Filed:

Mar 10, 2020

Appl. No.:

16/814339

Inventors:

- Miami FL, US
Vadim DEYEV - Miami FL, US
Robert LEVY - Cooper City FL, US

International Classification:

A61K 38/17
C07K 16/28
C07K 16/24
A61K 35/13
A61K 39/00
A61K 39/395
A61K 45/06

Abstract:

This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, e.g., to treat disease caused by asthma and chronic inflammation, such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein can inhibit CD8 T cell-mediated cellular immune responses and can, for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines. TNFR25 specific immunotoxins disclosed herein are also capable of increasing the effectiveness of a chemotherapeutic regimen by depleting a cancer patient of naturally occurring immunosuppressive cells.